James E Grace

发表

Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Joseph Payne, Vijay T. Ahuja, Yue-Zhong Shu, 2009, Journal of medicinal chemistry.

Production of recombinant human apoferritin heteromers.

S. Aust, M. Eden, James E Grace, 2000, Archives of biochemistry and biophysics.

In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Vijay T. Ahuja, J. Macor, H. Wong, 2009, Journal of medicinal chemistry.

Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534

J. Macor, D. Post‐Munson, T. Molski, 2013, Neuropharmacology.

Evaluation of Cynomolgus Monkey Pregnane X Receptor, Primary Hepatocyte, and in Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction

J. Dinchuk, James E Grace, Monique N. Anthony, 2010, Drug Metabolism and Disposition.

THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION

K. He, H. Wong, S. Diamond, 2004, Drug Metabolism and Disposition.

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

P. Lam, K. He, R. Knabb, 2011, European Journal of Drug Metabolism and Pharmacokinetics.

Design, synthesis, and evaluation of phenylglycinols and phenyl amines as agonists of GPR88.

Alan G. E. Wilson, Vijay T. Ahuja, Y. Liu, 2015, Bioorganic & medicinal chemistry letters.

Development and validation of a preclinical food effect model.

P. Marathe, D. G. Morgan, C. Gleason, 2007, Journal of pharmaceutical sciences.

Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF1) receptor antagonist BMS-665053 leading to improved oral bioavailability.

Vijay T. Ahuja, J. Macor, N. Lodge, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.

Vijay T. Ahuja, J. Macor, T. Molski, 2016, Bioorganic & medicinal chemistry letters.

A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Vijay T. Ahuja, J. Macor, Y. Shu, 2009, Journal of medicinal chemistry.

Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites.

D. Drexler, T. Zvyaga, James E Grace, 2012, Bioanalysis.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Alan G. E. Wilson, G. Shankar, S. Mandlekar, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

J. Macor, M. Ahlijanian, Joseph L. Cantone, 2014, International journal of Alzheimer's disease.

N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.

P. Lam, K. He, T. Olah, 2008, Journal of pharmaceutical sciences.

Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice

D. Thakker, C. Albright, S. Sankaranarayanan, 2015, Journal of Neuroscience.

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481

J. Macor, A. Mathur, M. Ahlijanian, 2019, ACS medicinal chemistry letters.

P-Glycoprotein Efflux and Other Factors Limit Brain Amyloid β Reduction by β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors in Mice

J. Macor, J. Marcinkeviciene, M. Ford, 2008, Journal of Pharmacology and Experimental Therapeutics.